期刊档案 · 医学-胃肠肝病学
Inflammatory Bowel Diseases
ISSN 1078-0998 · eISSN 1536-4844 · Oxford University Press · UNITED STATES · Monthly
Inflammatory Bowel Diseases 中科院 医学 3区(2025 年升级版),影响因子 5.34,混合开放获取,APC 约 3,862 美元,近 24 个月 109 篇文章投稿到接收中位 96 天,录用比例约20%(社区反馈),2025 年发文 517 篇,SCIE、Scopus 收录。
研究范围
研究范围与定位
Inflammatory Bowel Diseases 由 Oxford University Press 出版,属中科院医学大类(2025 升级版3区)。按 OpenAlex 近年发文统计,该刊主要发表 Inflammatory Bowel Disease、Microscopic Colitis、Autoimmune and Inflammatory Disorders 等主题的论文,这 3 个主题约占 56.1%。(根据 OpenAlex 主题统计与中科院分区数据生成)
Inflammatory Bowel Diseases® supports the mission of the Crohn's & Colitis Foundation by publishing research that will improve the quality of life of patients and bring us closer to cures. Each issue contains original basic science, translational, and clinical research regarding pathogenesis, epidemiology, evaluation, and treatment of inflammatory bowel disease (IBD) that will lead to advancements in overall clinical care. Articles published in Inflammatory Bowel Diseases® are from clinicians and researchers around the world and highlight unique and important issues in adult and pediatric IBD. We seek to publish novel and innovative research that will have a positive impact on the lives of children and adults with IBD. The journal does not accept case reports. Inflammatory Bowel Diseases® is the official journal of the Crohn's & Colitis Foundation. We invite you to read more about the Foundation's mission and core values. Journal metrics Citation metrics Clarivate 2025 Impact Factor 5.5 2025 5 Year Impact Factor 5.7 Gastroenterology & Hepatology (Rank by Impact Factor) 30/153 Scopus 2025 CiteScore 9.2 Gastroenterology (Rank by CiteScore) 16/176 About metrics Disclaimer Statements of fact and opinion in the articles in Inflammatory Bowel Diseases are those of the respective authors and contributors and not of the Journal, Crohn's & Colitis Foundation, or Oxford University Press, unless otherwise expressly indicated. Neither Oxford University Press, Crohn's & Colitis Foundation, nor the Journal make any representation, express or implied, in respect of the accuracy of the material in the Journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. Readers should make their own evaluation as to the appropriateness or otherwise of the information included. Becoming digital-only Starting in January 2024, Inflammatory Bowel Diseases® will be transitioning to a digital-only format, shrinking our footprint while providing an even more immersive and immediate reading experience for you. Going digital demonstrates our commitment to top-notch, cutting-edge research while allowing us to enhance the content, interactivity, and accessibility of our journal, ensuring you have seamless access to the latest IBD updates. Embracing the digital frontier means readers will enjoy: Instant Access: No more waiting for your journal to arrive in the mail. Readers are guaranteed access to the most current versions of all articles at a
摘自期刊官网 Aims & Scope
研究方向(LetPub):医学-胃肠肝病学
主编 Sonia Friedman出版商官网
编委会国家分布:中国大陆 2 位(约 2%);主要国家 美国 73、意大利 4、英国 3、加拿大 3、中国 2(共 101 位编委标注了国家) 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计,占比为近似值
- Inflammatory Bowel DiseaseBiochemistry, Genetics and Molecular Biology36.3%
- Microscopic ColitisMedicine15.2%
- Autoimmune and Inflammatory DisordersMedicine4.5%
- Gut microbiota and healthBiochemistry, Genetics and Molecular Biology4.3%
- Eosinophilic EsophagitisMedicine3.8%
- Gastrointestinal motility and disordersMedicine2.7%
- Helicobacter pylori-related gastroenterology studiesMedicine2.7%
- Liver Diseases and ImmunityMedicine2.6%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表( 2025年3月升级版)医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 胃肠肝病学GASTROENTEROLOGY & HEPATOLOGY | 3 区 |
Top 期刊:否综述期刊:否
《新锐期刊分区表》( 2026年3月发布)医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 胃肠肝病学GASTROENTEROLOGY & HEPATOLOGY | 3 区 |
Top 期刊:否综述期刊:未标注
期刊分区表( 2023年12月旧的升级版)医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 胃肠肝病学GASTROENTEROLOGY & HEPATOLOGY | 3 区 |
Top 期刊:否综述期刊:否
数据库收录
SCIEScopusLetPub
国际期刊预警名单:各版本均未列入LetPub
不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 5.34LetPub ·
- 影响因子(出版商公布) 2025
- 9.2出版商官网 ·
- 五年影响因子(出版商公布) 2025
- 5.7出版商官网 ·
- CiteScore 2026-06
- 9.2LetPub ·
- CiteScore(出版商公布) 2025
- 9.2出版商官网 ·
- SJR 2026-06
- 1.93LetPub ·
- SNIP 2026-06
- 1.5LetPub ·
- h-index
- 128LetPub ·
- h-index
- 211OpenAlex ·
- i10-index
- 5,239OpenAlex ·
- 两年平均被引
- 2.67OpenAlex ·
- 自引率
- 5.5%LetPub ·
- Gold OA 文章占比
- 28.53%LetPub ·
发文规模
- 年文章数
- 221LetPub ·
逐年发文量 OpenAlex 统计 · 累计 13,369 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 355 | 99 | 81 |
| 2025 | 517 | 243 | 954 |
| 2024 | 509 | 404 | 2,658 |
| 2023 | 489 | 389 | 4,576 |
| 2022 | 473 | 313 | 4,834 |
| 2021 | 504 | 206 | 6,567 |
不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
96 天投稿到接收中位数 · P25–P75 64 天 – 146 天
- 接收到上线
- 中位数 28 天(50 篇)
- 投稿到上线
- 中位数 128 天
- 样本
- 109 篇有投稿与接收日期的文章(窗口内共 819 篇),最近一篇接收于
只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度(社区反馈)
- 平均1月LetPub ·
- 平均录用比例(社区反馈)
- 20%LetPub ·
- 评审方式
- 单盲同行评审出版商官网
社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
订阅期刊,作者可付费选择开放获取发表。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| OpenAlex | USD 3,862 | — | — |
混合期刊的文章处理费仅在作者选择开放获取发表时收取;按订阅方式发表通常不收费。
其他费用与减免(作者指南)
- 投稿费
- 无投稿费
费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。
投稿要求
文章类型与投稿政策(官网)
投稿准备要点8 项,摘自作者指南
- 摘要
- ≤ 250 词
- 关键词
- 3–5 个
- 正文篇幅
- ≤ 7,000 词
- 参考文献格式
- 顺序编码制(按引用顺序编号)
- 首次投稿格式
- 允许不按期刊格式排版(free format)
- Highlights(研究亮点)
- 必须提供
- 图文摘要
- 可选
- 投稿信(Cover letter)
- 必须提供
接收的文章类型9 种
- brief reportBasic, translational, and clinical articles submitted to IBD should be submitted as one of the following article types using the parameters below. Review Articl…未说明篇幅
- brief reportsBrief Reports should be classified as either Basic Science, Translational, or Clinical and should be concise communications of original research.未说明篇幅
- letters to the editorLetters in response to articles published in the Journal are welcome.未说明篇幅
- original articleBasic, translational, and clinical articles submitted to IBD should be submitted as one of the following article types using the parameters below. Review Articl…未说明篇幅
- original articlesOriginal Articles should be classified as Basic Science, Translational, or Clinical, should add to the body of knowledge of Crohn's disease and ulcerative colit…未说明篇幅
- original researchBasic, translational, and clinical articles submitted to IBD should be submitted as one of the following article types using the parameters below. Review Articl…未说明篇幅
- reviewBasic, translational, and clinical articles submitted to IBD should be submitted as one of the following article types using the parameters below. Review Articl…未说明篇幅
- review articleBasic, translational, and clinical articles submitted to IBD should be submitted as one of the following article types using the parameters below. Review Articl…未说明篇幅
- review articlesReview Articles should be classified as Basic Science, Translational, or Clinical and should present recent advances in a relatively narrow topic that have been…未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、出版伦理、许可与版权、开放获取、同行评审、查重、预印本
- AI 使用
由人工智能驱动的自然语言处理工具不具备作者资格,期刊将在作者名单中对其进行筛查。 模型中文摘要
Natural language processing tools driven by artificial intelligence (AI) do not qualify as authors, and the Journal will screen for them in author lists.
原文 ↗出版商官网 ·- 作者资格 Authorship
每位署名作者均应遵循国际医学期刊编辑委员会(ICMJE)提出的作者资格标准;符合共同作者条件的已故人员应被列入,并在作者信息注释中注明其去世日期。 模型中文摘要
Each person listed as an author is expected to follow the authorship criteria put forth by the ICMJE. Deceased persons who meet the criteria for inclusion as coauthors should be so included, with an Author Information note indicating the date of death. In submitting to IBD, authors are expected to honor all deadlines presented to them. Authors are expected to respond to all communication from the …
原文 ↗出版商官网 ·- 利益冲突 Policies on Conflicts of Interest
利益冲突指可能影响或被认为可能影响作者、审稿人和编辑判断的竞争性利益;利益冲突被视为在撰写、审阅或编辑该稿件之前三年内的关系。 模型中文摘要
IBD is committed to making transparent the Journal’s policies on Conflict of Interest as they relate to authors, reviewers, and editors. Authors should familiarize themselves with the below points as well as COPE’s Guidelines on Good Publication Practice before committing to working with the Journal. Conflicts in regard to publication can occur when a competing interest may influence or be perceiv…
原文 ↗出版商官网 ·- 数据可用性 Availability of Data and Materials
在伦理允许的情况下,期刊强烈鼓励作者公开论文结论所依据的所有数据和软件代码,建议将数据呈现在正文或附加支持文件中,或尽可能存入公共存储库。 模型中文摘要
Where ethically feasible, IBD strongly encourages authors to make all data and software code on which the conclusions of the paper rely available to readers. We suggest that data be presented in the main manuscript or additional supporting files, or deposited in a public repository whenever possible. For information on general repositories for all data types, and a list of recommended repositories…
原文 ↗出版商官网 ·- 出版伦理 Ethical Considerations
投稿稿件必须是未曾发表过的原创贡献(摘要或初步报告除外),不得同时被其他刊物考虑发表;投稿前在社区预印本服务器或在线会议演示中存放稿件不被视为先前发表。 模型中文摘要
A submitted manuscript must be an original contribution not previously published (except as an abstract or preliminary report), must not be under consideration for publication elsewhere, and, if accepted, must not be published elsewhere in similar form, in any language, without the consent of the publisher. Deposition of manuscripts prior to submission on community preprint servers or on conferenc…
原文 ↗出版商官网 ·- 许可与版权 Exclusive License
在《Inflammatory Bowel Diseases》发表的条件是作者向克罗恩与结肠炎基金会授予专有许可;作者可在承认该期刊为原始发表地点及牛津大学出版社为出版者的前提下,在其他出版物中使用自己的材料。 模型中文摘要
It is a condition of publication in Inflammatory Bowel Diseases that authors grant an exclusive license to the Crohn’s & Colitis Foundation. This ensures that requests from third parties to reproduce articles are handled efficiently and consistently and will also allow the article to be as widely disseminated as possible. As part of the license agreement, authors may use their own material in othe…
原文 ↗出版商官网 ·- 开放获取 Open Access Publication Fee Information
期刊提供标准许可或开放获取许可两种发表选项;若选择开放获取发表,需在文章被接受后在在线系统中选择开放获取许可,并支付开放获取费用。 模型中文摘要
IBD offers the option of publishing under either a standard license or an Open Access license. Please note that some funders require Open Access publication as a condition of funding. If you are unsure whether you are required to publish Open Access, please do clarify any such requirements with your funder or institution. Should you wish to publish your article Open Access, you should select your …
原文 ↗出版商官网 ·- 同行评审 Peer Review
编辑阅读所有投稿;符合质量标准、被认为能推动该领域发展且符合期刊范围的稿件将交由副编辑并送外部专家进行单盲同行评审,即作者身份对编辑和审稿人公开,而审稿人身份仅对编辑公开并对作者隐藏。 模型中文摘要
The Editors read all manuscript submissions. All manuscripts that meet the quality standards, are felt to advance the field, and adhere to the scope of the Journal are assigned to an Associate Editor and sent to outside experts for peer review using a single-anonymized system, meaning that authors’ identities are known to the Editor and to the reviewers, but that the reviewers’ identities are know…
原文 ↗出版商官网 ·- 查重 Plagiarism
所有论文必须无剽窃;剽窃包括未加引用地使用作者本人或他人的已发表或未发表的工作或观点,编辑人员可能会使用iThenticate软件对投稿稿件进行分析。 模型中文摘要
All papers must be free of plagiarism. Plagiarism includes the unreferenced use of the author’s own work or ideas or the work or ideas of others, either published or unpublished. It may occur at any stage of the development of a manuscript and it applies to print and electronic versions of the work. Authors should consult the Committee on Publication Ethics’ (COPE) Guidelines on Good Publication P…
原文 ↗出版商官网 ·- 预印本
投稿前在社区预印本服务器或在线会议演示中存放稿件不被视为先前发表,也不会影响其在《IBD》的潜在发表。 模型中文摘要
Deposition of manuscripts prior to submission on community preprint servers or on conference presentations online will not be considered prior publication and will not compromise potential publication in IBD.
原文 ↗出版商官网 ·
摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Oxford University Press
- 出版国家或地区
- UNITED STATES
- 出版语言
- English
- 出版周期
- Monthly
- ISSN
- 1078-0998
- 电子版 ISSN
- 1536-4844
- 学会 / 主办单位
- Crohn's & Colitis Foundation
- 官网最新一期
- Volume 32, Issue 9(2026 年 9 月)
- 官方链接
- 期刊主页 ↗LetPub
- 投稿系统 ↗出版商官网
- 专刊 / 特刊征稿 ↗出版商官网
常见问题
关于 Inflammatory Bowel Diseases 的常见问题
Inflammatory Bowel Diseases 是中科院几区期刊?
2025 年升级版分区表中,Inflammatory Bowel Diseases 为医学 3区,小类 胃肠肝病学 3 区。2026 年新锐版分区表中为医学 2区。不同版本与大小类分区不能混用。
Inflammatory Bowel Diseases 的影响因子是多少?
LetPub 汇总的最新公布影响因子为 5.34,CiteScore 为 9.2,h-index 为 211。
Inflammatory Bowel Diseases 的审稿周期多长?
按 2024年10月至2026年10月(近 24 个月)109 篇已发表文章登记的日期,投稿到接收的中位数为 96 天(四分位 64–146 天);投稿社区反馈的平均审稿速度为约 1 个月,平均录用比例反馈为“约20%”。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。
Inflammatory Bowel Diseases 的投稿格式要求是什么?
据期刊作者指南:摘要:≤ 250 词;关键词:3–5 个;正文篇幅:≤ 7,000 词;参考文献格式:顺序编码制(按引用顺序编号);首次投稿格式:允许不按期刊格式排版(free format);Highlights:必须提供;图文摘要:可选;投稿信:必须提供。以上由模型从作者指南提取并逐项与原文核对,投稿前请以官网最新版本为准。
Inflammatory Bowel Diseases 的编委会里有中国学者吗?
期刊官网编委会页面上标注了国家的 101 位编委中,中国大陆 2 位(约 2%);人数最多的国家是 美国(73 位)、意大利(4 位)、英国(3 位)。统计按编委会页面列出的机构国家计,仅供参考。
Inflammatory Bowel Diseases 被哪些数据库收录?
据 LetPub 与 DOAJ 记录,Inflammatory Bowel Diseases 被 SCIE、Scopus 收录。
Inflammatory Bowel Diseases 是开放获取期刊吗?版面费多少?
Inflammatory Bowel Diseases 为混合开放获取。选择开放获取发表时APC 约 3,862 美元。
来源与更新
本页事实来自 LetPub、OpenAlex、出版商官网;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-25 归档)。最近更新:。